Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00850044 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
A Phase 1 study of HCV Infection, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT00850044 is a Phase 1 study of HCV Infection that has completed, run by AbbVie. The registered enrollment target is 87 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00850044, a Phase 1 study of HCV Infection, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
Conditions Studied
Interventions
- DRUG ritonavir
- DRUG ABT-450
- DRUG placebo for ABT-450
- DRUG Placebo for ritonavir
Study Locations (1)
Illinois
- Site Reference ID/Investigator# 15981 - Waukegan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00850044
The ClinicalTrials.gov registry entry for NCT00850044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HCV Infection appearing as the primary indexed condition, and to 4 interventions - of which ritonavir is the first listed.
NCT00850044 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00850044 about?
NCT00850044 is a clinical study titled "Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1". The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
What is the current status of trial NCT00850044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2009-02.
What conditions does trial NCT00850044 study?
This clinical trial studies the following conditions: HCV Infection.
What interventions are being tested in trial NCT00850044?
The interventions under investigation include: ritonavir (DRUG), ABT-450 (DRUG), placebo for ABT-450 (DRUG), Placebo for ritonavir (DRUG).
Who is sponsoring clinical trial NCT00850044?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00850044 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.